search
Back to results

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Primary Purpose

Lymphoma, Large-Cell

Status
Withdrawn
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
MDX-060
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lymphoma, Large-Cell focused on measuring ALCL, csALCL, pcALCL, Lymphoma, Non-Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma, classic systemci Anaplastic Large Cell Lymphoma (csALCL), primary cutaneous Anaplastic Large Cell Lymphoma (pcALCL)

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: signed informed consent confirmed diagnosis of ALCL patient with csALCL must be confirmed CD30+ patients with csALCL must have failed or relapsed following second line (i.e. salvage) chemotherapy or relapsed or failed following autologous stem cell transplant. patients with pcALCL must have progressed after treatment with local radiation therapy or surgical excision or failed systemic therapy with a single agent or multi-agent regimen. patients with pcALCL must be confirmed CD30+ ECOG performance of 0 to 2 at least 12 years of age life expectancy 12 weeks or greater must meet screening laboratory values women must be post-menopausal for at least 1 year; surgically incapable of bearing children; or utilizing a reliable form of contraception. All women must have a negative pregnancy test. men must agree to the use of male contraception for the duration of the study patients on corticosteroids must be tapered off the medication 2 weeks prior to the first MDX-060 administration and remain off corticosteroids until day 365. Exclusion Criteria: previous treatment with any anti-CD30 antibody history of allogenic transplantation any tumor lesion 10 cm or greater in diameter any other malignancy, excluding basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ. Any cancer from which the patient has been disease free for at least 5 years is permissible. any significant acter or chronic infection. prior known serum positivity for HIV, hepatitis B or C as determined at screening. treatment with an investigational agent within 30 days or 5 half-lives (whichever is longer) of study screening. apparent active or latent tuberculosis infection (TB). patients who are pregnant or nursing any underlying medical condition which, in the investigator's opinion, will make the administration of MDX-060 hazardous or obscure the interpretation of adverse events. concomitant chemotherapy, corticosteroids, investigational agents, other anti-ALCL biologics, or radiation therapy patients with mycosis fungoides, or patients with recurrent, self-healing papulonodular eruptions only or any other lymphoma other than ALCL.

Sites / Locations

  • City of Hope, National Medical Center
  • California Oncology of the Central Valley
  • Moores UCSD Cancer Center
  • Mayo Clinic
  • The Cancer Institute of New Jersey - Robert Wood Johnson Unv. Hosp.
  • Roswell Park Cancer Center
  • Carolina BioOncology Institute
  • Centre Hospitalier Regional Unv. de Lille, Hopital Claude Huriez

Outcomes

Primary Outcome Measures

Objective response rate
progression free survival
response duration
Quality of Life
Immunogenicity
best objective response rate
safety

Secondary Outcome Measures

Full Information

First Posted
March 1, 2006
Last Updated
April 23, 2010
Sponsor
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT00298467
Brief Title
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Official Title
An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Study Type
Interventional

2. Study Status

Record Verification Date
April 2010
Overall Recruitment Status
Withdrawn
Why Stopped
sponsor decision
Study Start Date
February 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Bristol-Myers Squibb

4. Oversight

5. Study Description

Brief Summary
This study is an open-label, fixed-dose, multicenter study of MDX-060 in patients with ALCL who have relapsed or refractory disease. There will be 3 phases of this study: Induction, Maintenance, and Follow-up. Patients will be required to attend all protocol-required visits in the 4-week Induction Phase, in which administration of MDX-060 will occur, as well as other testing. Patients who complete the Induction Phase may be eligible for additional MDX-060 treatment ever 2 months for 1 year in the Maintenance Phase. Patients who complete the Maintenance Phase with a response of stable disease or better will be followed every 2 months for 1 year or until disease progression. The purpose of this study is to determine objective response rate at Day 50 in patients with relapsed or refractory classic systemic ALCL or primary cutaneous ALCL treated with MDX-060. Other objectives will be evaluated.
Detailed Description
This study is an open-label, fixed-dose, multicenter study of MDX-060 in patients with ALCL who have relapsed or refractory disease. There will be 3 phases of this study: Induction, Maintenance, and Follow-up. Patients will be required to attend all protocol-required visits in the 4-week Induction Phase, in which administration of MDX-060 will occur, as well as other testing. Patients who complete the Induction Phase may be eligible for additional MDX-060 treatment ever 2 months for 1 year in the Maintenance Phase. Patients who complete the Maintenance Phase with a response of stable disease or better will be followed every 2 months for 1 year or until disease progression. The primary objective of the study is to determine the objective response rate (ORR) at Day 50 in patients with relapsed or refractory classic systemic anaplastic large cell lymphoma (csALCL) or primary cutaneous ALCL (pcALCL) treated with MDX-060. The ORR will be based on an adaption of the NCI Response Criteria for Non-Hodgkin's Lymphoma (NHL) for patients with csALCL and will be based on the Physician's Global Assessment (PGA) for patient with pcALCL. Secondary objectives include 1) characterizing progression-free survival (PFS); 2) determining response duration (RD); 3) characterizing the effect of MDX-060 on health-related Quality of Life (QoL); 4) evaluating patients with pcALCL using an adaption of the NCI Response Criteria for NHL; 5) characterizing the immunogenicity of MDX-060; 6) characterizing the safety of MDX-060; and 7) determining the best objective response rate (BORR) during the Maintenance Phase of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphoma, Large-Cell
Keywords
ALCL, csALCL, pcALCL, Lymphoma, Non-Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma, classic systemci Anaplastic Large Cell Lymphoma (csALCL), primary cutaneous Anaplastic Large Cell Lymphoma (pcALCL)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
45 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
MDX-060
Primary Outcome Measure Information:
Title
Objective response rate
Title
progression free survival
Title
response duration
Title
Quality of Life
Title
Immunogenicity
Title
best objective response rate
Title
safety

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: signed informed consent confirmed diagnosis of ALCL patient with csALCL must be confirmed CD30+ patients with csALCL must have failed or relapsed following second line (i.e. salvage) chemotherapy or relapsed or failed following autologous stem cell transplant. patients with pcALCL must have progressed after treatment with local radiation therapy or surgical excision or failed systemic therapy with a single agent or multi-agent regimen. patients with pcALCL must be confirmed CD30+ ECOG performance of 0 to 2 at least 12 years of age life expectancy 12 weeks or greater must meet screening laboratory values women must be post-menopausal for at least 1 year; surgically incapable of bearing children; or utilizing a reliable form of contraception. All women must have a negative pregnancy test. men must agree to the use of male contraception for the duration of the study patients on corticosteroids must be tapered off the medication 2 weeks prior to the first MDX-060 administration and remain off corticosteroids until day 365. Exclusion Criteria: previous treatment with any anti-CD30 antibody history of allogenic transplantation any tumor lesion 10 cm or greater in diameter any other malignancy, excluding basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ. Any cancer from which the patient has been disease free for at least 5 years is permissible. any significant acter or chronic infection. prior known serum positivity for HIV, hepatitis B or C as determined at screening. treatment with an investigational agent within 30 days or 5 half-lives (whichever is longer) of study screening. apparent active or latent tuberculosis infection (TB). patients who are pregnant or nursing any underlying medical condition which, in the investigator's opinion, will make the administration of MDX-060 hazardous or obscure the interpretation of adverse events. concomitant chemotherapy, corticosteroids, investigational agents, other anti-ALCL biologics, or radiation therapy patients with mycosis fungoides, or patients with recurrent, self-healing papulonodular eruptions only or any other lymphoma other than ALCL.
Facility Information:
Facility Name
City of Hope, National Medical Center
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Facility Name
California Oncology of the Central Valley
City
Fresno
State/Province
California
ZIP/Postal Code
93710
Country
United States
Facility Name
Moores UCSD Cancer Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
The Cancer Institute of New Jersey - Robert Wood Johnson Unv. Hosp.
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08901
Country
United States
Facility Name
Roswell Park Cancer Center
City
Buffalo
State/Province
New York
ZIP/Postal Code
14263
Country
United States
Facility Name
Carolina BioOncology Institute
City
Huntersville
State/Province
North Carolina
ZIP/Postal Code
28078
Country
United States
Facility Name
Centre Hospitalier Regional Unv. de Lille, Hopital Claude Huriez
City
Lille
ZIP/Postal Code
59037
Country
France

12. IPD Sharing Statement

Learn more about this trial

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

We'll reach out to this number within 24 hrs